Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $23,480.00 in Stock

Posted by Donald Scott on Mar 16th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $11.74, for a total value of $23,480.00. Following the completion of the transaction, the president now directly owns 2,835,260 shares of the company’s stock, valued at approximately $33,285,952.40. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Songjiang Ma also recently made the following trade(s):

On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total value of $20,280.00.
On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total value of $20,500.00.
On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total value of $23,800.00.
On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.62, for a total value of $23,240.00.
On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total value of $22,860.00.
On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total value of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.

Gyre Therapeutics Stock Performance

Shares of Gyre Therapeutics stock opened at $12.11 on Friday. The business has a 50-day moving average of $11.27 and a 200 day moving average of $12.31. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $19.00.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GYRE. Geode Capital Management LLC boosted its stake in shares of Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after buying an additional 43,840 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Gyre Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock valued at $1,386,000 after buying an additional 918 shares during the period. State Street Corp boosted its stake in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after buying an additional 8,412 shares during the period. Northern Trust Corp boosted its stake in shares of Gyre Therapeutics by 9.1% in the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock valued at $1,251,000 after buying an additional 8,624 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Gyre Therapeutics during the 4th quarter worth about $1,225,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Noble Financial started coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating for the company.

Check Out Our Latest Research Report on Gyre Therapeutics

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.